Navigation Links
GeoPharma Announces Third Quarter Conference Call

LARGO, Fla., Jan. 31 /PRNewswire-FirstCall/ -- GeoPharma, Inc. (Nasdaq: GORX) announced today that it will host a conference call to discuss the results of its third fiscal quarter ended December 31, 2007 on Thursday, February 14, 2008 at 11:30 a.m. (ET) with CEO, Mihir Taneja and VP/CFO, Carol Dore-Falcone. Participants may pre-register for the conference call by utilizing the following URL, thus avoiding operator assistance hold time and ensuring a spot in the queue. Participants may also dial in to register the day of the conference call 5 minutes before, or 11:25 a.m. The dial in number for participants is 1-888-286-8010, pass code 78555682. The Company will release the Company's operating results before trading the day of the call. Conference call replay will be available by dialing 1-888-286-8010 pass code 37538422 on February 14, 2008 at 1:30 p.m. through February 21, 2008.

GeoPharma, Inc. is a rapidly growing Bio/Pharma company with a diversified business model participating in 3 main market segments: Specialty Pharma, Manufacturing, and Distribution. The Specialty Pharma division specializes in the formulation of generic drugs for human and veterinary usage and the development of medical devices used by oncologists and other medical professionals. The Manufacturing and Distribution divisions, manufacture, package, and distribute generic drugs, nutraceuticals, cosmetics, and functional food products for companies worldwide.

GeoPharma's growth strategy is to capitalize on its research and manufacturing expertise to develop medical devices and high margin generic drug products for niche markets with high barriers to entry. GeoPharma's competitive advantage in these areas is in its ability to navigate the challenges that such market pursuits present effectively.

Currently GeoPharma employs nearly 300 people and operates facilities in Florida, Maryland, Pennsylvania, Nevada, Rhode Island, and Texas utilizing over 330,000 Sq. Ft. of office, warehouse, manufacturing and laboratory facilities.

For further information visit the "For Investors" section of the GeoPharma website at

This press release may contain statements, which constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those regarding the company and its subsidiaries' expectations, intentions, strategies and beliefs pertaining to future performance. All statements contained herein are based upon information available to the company's management as of the date hereof, and actual results may vary based upon future events, both within and without management's control. Important factors that could cause such differences are described in the company's periodic filings with the Securities and Exchange Commission.

SOURCE GeoPharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. GeoPharma, Inc. Receives FDA Approval to Manufacture and Distribute Carprofen
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
(Date:11/30/2015)... Israel , Nov. 30, 2015 ... leading developer of adult stem cell technologies for neurodegenerative diseases, ... has been awarded an additional grant of approximately $735,000 from ... (OCS). This grant, the second this year, brings the total ... $1.8 million (approximately NIS7 million).  ...
(Date:11/27/2015)... Nov. 27, 2015 /PRNewswire/--  Mallinckrodt plc (NYSE: ... that it has closed the sale of its global ... (GBT- NYSE Euronext) in a transaction valued at approximately ... facilities and a total of approximately 1,000 employees spread ... St. Louis area. This entire workforce ...
(Date:11/27/2015)... , November 27, 2015 ... Growing popularity of companion diagnostics is ... cancer biomarkers market with pharmaceutical companies and ... companion diagnostic tests. . ... Complete report on global cancer biomarkers ...
(Date:11/26/2015)... , November 26, 2015 --> ... company specializing in imaging technologies, announced today that it has ... part of the Horizon 2020 European Union Framework Programme for ... large-scale clinical trial in breast cancer. , ... --> --> The study ...
Breaking Biology Technology:
(Date:11/11/2015)... MedNet Solutions , an innovative SaaS-based eClinical technology company that ... announce that it will be a Sponsor of the ... held November 17-19 in Hamburg , Germany.  ... iMedNet , MedNet,s easy-to-use, proven and affordable eClinical ... able to deliver time and cost savings of up to ...
(Date:11/9/2015)... , Nov. 09, 2015 ... the addition of the "Global Law ... their offering. --> ) ... "Global Law Enforcement Biometrics Market 2015-2019" ... Research and Markets ( ) has ...
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has ... to provide preclinical development services to the National Cancer ... SRI will provide scientific expertise, modern testing and support ... of preclinical pharmacology and toxicology studies to evaluate potential ... --> The PREVENT Cancer Drug Development Program is ...
Breaking Biology News(10 mins):